Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiles of non-recurrent human glioblastoma tissues

ABSTRACT: Gene expression profiles of non-recurrent human glioblastoma tissues

PROVIDER: PRJNA545098 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiles of non-recurrent human glioblastoma tumorspheres

Project description:Gene expression profiles of non-recurrent human glioblastoma tumorspheres

| PRJNA667330 | ENA

Gene expression profiles of non-recurrent human glioblastoma tissues

Project description:Samples were obtained from 52 non-recurrent GBM patients treated at Severance Hospital

2019-05-29 | GSE131837 | GEO

Expression pattern of circRNA in primary and recurrent glioblastoma.

Project description:Circular RNAs are single-stranded covalently closed non-coding RNAs expressed in a variety of tissues and cells. Glioblastoma (GBM) is the most aggressive and lethal tumor in the central nervous system, characterized by high recurrence and mortality rates. Here we explore circRNA expression profiles in 26 primary and 3 recurrent GBM samples and compare them to healthy brain tissue. Additionally we compare expression of circRNA in GBM patients blood in comparison to healthy donor blood.

2024-06-29 | GSE196695 | GEO

Gene expression profiles of non-recurrent human glioblastoma tumorspheres

Project description:Samples were obtained from 23 non-recurrent GBM patients treated at Severance Hospital

2020-10-06 | GSE159000 | GEO

miRNA profiles in Primary and Recurrent GBM

Project description:Glioblastoma (GBM) bears a dismal prognosis with rapid relapse following complete resection and radiochemotherapy. The involvement of microRNAs in tumor progression has been demonstrated in hepatoma, breast cancer, and prostate cancers. However, the microRNAs involved in modulating the progression and relapse of GBM are still unclear. Initially, we compared the miRNA expression profiles between primary and recurrent GBM tissues from the same patient in twelve independent cases. miRNA expression profiles between primary and recurrent GBM tissues from the same patient in twelve independent cases.

2014-09-28 | E-GEOD-32466 | biostudies-arrayexpress

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Project description:Purpose: To identify transcriptional changes by RNA-seq in tumor samples, before bevacizumab combination treatment and after bevacizumab combination treatment in both responding and non-responding recurrent glioblastoma patients

2017-04-20 | GSE79671 | GEO

miRNA profiles in Primary and Recurrent GBM

2014-09-28 | GSE32466 | GEO

Multi-omics profiling of paired primary and recurrent glioblastoma patient tissues

Project description:Background Despite maximal therapy with surgery, chemotherapy and radiotherapy, glioblastoma multiforme (GBM) patients have a median survival of only 15 months. Almost all patients inevitably experience symptomatic tumor recurrence. A hallmark of this tumor type is the large heterogeneity between patients and within tumors itself which relate to failure of standardized tumor treatment. In this study, tissue samples of paired primary and recurrent GBM tumors were investigated to identify individual factors related to tumor progression. Methods Paired primary and recurrent GBM tumor tissues from 8 patients were investigated with a multi-omics approach using transcriptomics, proteomics and phosphoproteomics. Results In the studied patient cohort, large variations between and within patients are observed for all omics analyses. A few pathways affected at the different omics levels partly overlapped if patients are analyzed at the individual level, such as synaptogenesis (containing the SNARE complex) and cholesterol metabolism. Phosphoproteomics revealed increased STMN1(S38) phosphorylation that relates to ERBB4 signaling. A pathway tool has been developed to visualize and compare the different omics datasets per patient and showed potential therapeutic drugs, such as abobotulinumtoxina and afatinib, that target these affected pathways. Afatinib targeting ERBB4 signaling is currently in clinical trials for GBM. Conclusions Large variation on all omics levels exist between and within GBM patients. Therefore, it will be rather unlikely to find a drug treatment that would fit all patients. Instead a multi-omics approach can be used to identify affected pathways on the individual patient level and select potential treatment options.

2020-11-17 | PXD017952 | Pride

Genomic-Enabled Medicine for Recurrent Glioblastoma

Project description:Genomic-Enabled Medicine for Recurrent Glioblastoma

| PRJNA408009 | ENA

Genomic-Enabled Medicine for Recurrent Glioblastoma

Project description:Genomic-Enabled Medicine for Recurrent Glioblastoma

| PRJNA408010 | ENA